Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients | Zendy

Deepika Slawek | Zendy; Diana Altshuler | Zendy; Yanina Dubrovskaya | Zendy; Eddie Louie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients

Author(s) -

Deepika Slawek,

Diana Altshuler,

Yanina Dubrovskaya,

Eddie Louie

Publication year - 2017

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofx184

Subject(s) - tigecycline , legionnaires' disease , medicine , intensive care medicine , pathogenic organism , linezolid , antibiotics , microbiology and biotechnology , legionella pneumophila , vancomycin , staphylococcus aureus , genetics , bacteria , biology

Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research